Antibody-mediated rejection (ABMR) is one of the leading causes of graft loss in kidney transplant recipients (KTRs). Although it is a well characterized entity, there is limited data regarding effective treatment options for preserving graft functions. Moreover, results from different studies have been contradictory. Therefore, we conducted a study using our registry data to evaluate the effects of a standardized treatment approach consisting of therapeutic plasma exchange (regular plasmapheresis, double filtration plasmapheresis or immunoadsorption), intravenous immunoglobulin and rituximab on KTRs with acute or chronic ABMR.
Study Type
OBSERVATIONAL
Enrollment
75
Istanbul University
Istanbul, Turkey (Türkiye)
Graft Loss
Returning to dialysis due to graft failure or death with a functioning graft.
Time frame: 2-5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.